HC Wainwright Predicts Agenus' Q3 Earnings (NASDAQ:AGEN)

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Agenus Inc. to $2.63 per share, significantly up from a prior estimate of $0.25. The firm maintains a "Buy" rating with a price target of $25.00.
• Agenus recently reported a quarterly loss of ($1.00) EPS for Q2, which missed analyst expectations of ($0.78) EPS and generated revenues of only $25.70 million.
• Institutional investors hold 61.46% of Agenus' stock, with several firms, including Bank of Montreal and Gilead Sciences, making significant purchases in the recent quarter.

Agenus Inc. (NASDAQ:AGEN - Free Report) - Stock analysts at HC Wainwright increased their Q3 2025 earnings estimates for Agenus in a research note issued on Tuesday, August 12th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn $2.63 per share for the quarter, up from their previous estimate of $0.25. HC Wainwright currently has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Agenus' current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus' Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at $0.03 EPS, FY2026 earnings at ($1.61) EPS, FY2027 earnings at ($3.35) EPS, FY2028 earnings at ($3.40) EPS and FY2029 earnings at ($0.71) EPS.

Agenus (NASDAQ:AGEN - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.22). The business had revenue of $25.70 million for the quarter, compared to analyst estimates of $49.71 million.

Other analysts have also recently issued reports about the company. B. Riley reaffirmed a "buy" rating on shares of Agenus in a report on Monday, April 21st. Wall Street Zen raised shares of Agenus from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Robert W. Baird upped their price target on shares of Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a research note on Wednesday, June 4th.

Agenus Stock Performance

Shares of Agenus stock opened at $4.54 on Thursday. The company's 50 day moving average price is $5.40 and its 200-day moving average price is $3.69. Agenus has a 52-week low of $1.38 and a 52-week high of $7.34. The stock has a market capitalization of $144.64 million, a price-to-earnings ratio of -0.63 and a beta of 1.62.

Institutional Investors Weigh In On Agenus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can purchased a new position in Agenus during the 4th quarter worth approximately $69,000. Barclays PLC grew its holdings in shares of Agenus by 17.7% during the 4th quarter. Barclays PLC now owns 32,737 shares of the biotechnology company's stock valued at $90,000 after acquiring an additional 4,924 shares in the last quarter. Gilead Sciences Inc. acquired a new stake in shares of Agenus in the 4th quarter valued at $635,000. Northern Trust Corp lifted its stake in shares of Agenus by 14.8% in the 4th quarter. Northern Trust Corp now owns 208,933 shares of the biotechnology company's stock valued at $572,000 after purchasing an additional 26,870 shares during the last quarter. Finally, B. Riley Financial Inc. acquired a new stake in shares of Agenus in the 4th quarter valued at $2,074,000. Institutional investors own 61.46% of the company's stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.